Change over period: —
NSE · MOREPENLAB
MOREPEN LAB.
-37.2% from the 52-week high · +174.3% above the low
Morepen Laboratories Ltd. engages in the manufacture and market of bulk drugs and pharmaceutical formulations. The company is headquartered in Gurgaon, Haryana and currently employs 1,649 full-time employees. The firm is engaged in the business of manufacturing, producing, developing, and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also the home health products. Its APIs include Apixaban, Edoxaban, Sitagliptin, Linagliptin, Empagliflozin, Atorvastatin, Loratadine, Desloratadine, Montelukast Sodium, Atorvastatin Calcium, Fexofenadine, Sitagliptin Phosphate, Vildagliptin and Rivaroxaban, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
The short version. MOREPEN LAB. reported revenue of ₹747 crore for Sep 2026, up 81.3% from a year earlier. Net profit was ₹89 crore (up 117.1% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 35.65% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
MOREPEN LAB. trades 37.2% below its 52-week high and 174.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹747 cr.
Sep 2026 net profit of ₹89 cr.
2.0 pts higher than a year earlier.
Revenue compounded at 8.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 747 | 570 | 485 | 484 | 412 | 425 | 466 | 453 |
| Net profit | 89 | 56 | 16 | 28 | 41 | 11 | 20 | 27 |
| Net margin % | 11.9 | 9.9 | 3.2 | 5.7 | 9.9 | 2.5 | 4.4 | 5.9 |
| EPS (₹) | 1.62 | 1.03 | 0.29 | 0.5 | 0.75 | 0.2 | 0.37 | 0.49 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1806 | 1812 | 1690 | 1418 | 1547 | 1188 | 853 | 769 |
| Net profit | 95 | 118 | 96 | 39 | 102 | 97 | 34 | 29 |
| Net margin % | 5.3 | 6.5 | 5.7 | 2.7 | 6.6 | 8.2 | 3.9 | 3.8 |
| EPS (₹) | 1.73 | 2.15 | 1.88 | 0.76 | 2.13 | 2.16 | 0.75 | 0.64 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 7.6% in Mar 2026; debt to equity is 0.16.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 7.6 | 10.2 | 11.3 | 5.1 |
| Return on capital % | 9.4 | 12.8 | 15.6 | 7.3 |
| EBITDA margin % | 9.5 | 10.5 | 10.1 | 6.0 |
| Net margin % | 5.2 | 6.5 | 5.6 | 2.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 8.7% | 8.8% |
| Profit CAGR | 34.9% | -0.5% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 1.21 pts over 8 quarters.
Up 0.07 pts over 8 quarters.
+3 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 35.65 | 35.65 | 35.65 | 35.65 | 35.65 | 35.65 | 35.65 | 35.65 | 0.0 |
| FII | 2.22 | 1.94 | 1.72 | 1.62 | 1.62 | 1.58 | 1.46 | 3.43 | +1.21 |
| DII | 1.64 | 1.67 | 1.51 | 1.5 | 1.25 | 1.25 | 1.28 | 1.71 | +0.07 |
| Public | 60.47 | 60.72 | 61.11 | 61.21 | 61.46 | 61.5 | 61.59 | 59.19 | -1.28 |
Mutual fund holdings · Oct 2026
6 schemes hold this stock
3 the month before.
- UNION ACTIVE MOMENTUM FUND2.1% of NAV
- Bandhan BSE Healthcare Index Fund0.25% of NAV
- Motilal Oswal BSE Healthcare ETF0.24% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET INDEX FUND0.03% of NAV
- Motilal Oswal BSE 1000 Index Fund0.02% of NAV
- ADITYA BIRLA SUN LIFE BSE TOTAL MARKET ETF0.02% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for MOREPEN LAB. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about MOREPEN LAB.
What is the MOREPEN LAB. share price?
MOREPEN LAB. (MOREPENLAB) last closed at ₹90.90, down 1.59% on the day. Its 52-week range is ₹33.68 to ₹146.97.
What is the market cap of MOREPEN LAB.?
MOREPEN LAB. has a market capitalisation of about ₹5,055 crore. Its price-to-earnings ratio is 27.1.
How are MOREPEN LAB.'s latest results?
MOREPEN LAB. reported revenue of ₹747 crore for Sep 2026, up 81.3% from a year earlier. Net profit was ₹89 crore (up 117.1% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 35.65% in Sep 2026, up 0.00 points over 8 quarters.
Who owns MOREPEN LAB.?
As of Sep 2026, shareholding was: Promoter 35.65%, FII 3.43%, DII 1.71%, Public 59.19%.
How many mutual funds hold MOREPEN LAB.?
6 mutual fund schemes held MOREPEN LAB. in October 2026. That compares with 3 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 Aug 2025 · Final Dividend - Rs. 0.2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.